Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
XPO1/CRM1 is a key nuclear exporter protein that mediates translocation of numerous cellular regulatory proteins. We investigated whether XPO1 is a potential therapeutic target in melanoma using novel selective inhibitors of nuclear export (SINE). In vitro effects of SINE on cell growth and apoptosi...
Main Authors: | Jennifer Yang, Matthew A Bill, Gregory S Young, Krista La Perle, Yosef Landesman, Sharon Shacham, Michael Kauffman, William Senapedis, Trinayan Kashyap, Jean-Richard Saint-Martin, Kari Kendra, Gregory B Lesinski |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4109950?pdf=render |
Similar Items
-
E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1
by: Bert Kwanten, et al.
Published: (2023-04-01) -
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
by: Xuejiao Liu, et al.
Published: (2016-10-01) -
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
by: Lijia Pan, et al.
Published: (2021-08-01) -
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
by: Basia Galinski, et al.
Published: (2021-08-01) -
Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
by: Md. Hafiz Uddin, et al.
Published: (2023-12-01)